Meta-analytic Phase II clinical trial
A meta-analytic Phase II clinical trial integrates individual or aggregate data from multiple single-arm or small Phase II studies into a unified meta-analytic framework. Rather than relying on a single underpowered trial to screen for activity, this design pools evidence across comparable cohorts to obtain a more reliable estimate of treatment response, enabling better-informed go/no-go decisions before committing to a large Phase III randomized trial.
Zdrojový záznam
Citácie skopírované doslovne zo zdrojového záznamu metódy. Nevyplýva z nich žiadne overenie na úrovni tvrdenia.
- Warmuth, M., & Hinzmann, B. (2013). Phase II trials in oncology: From the statistical design of trials to the meta-analysis of the results. Onkologie, 36(9), 555–564. · URL
- Sutton, A. J., Cooper, N. J., Jones, D. R., Lambert, P. C., Thompson, J. R., & Abrams, K. R. (2007). Evidence-based sample size calculations based upon updated meta-analysis. Statistics in Medicine, 26(12), 2479–2500. · DOI 10.1002/sim.2704
Spracované tvrdenia
Tvrdenia uložené v registri dôkazov, každé s vlastným hodnotením.
Tento pohľad nevymýšľa hodnotenie tvrdenia, ak register žiadne nemá.
Súvisiace metódy
Vygenerované z grafu metód a zobrazené ako vzťahy navrhnuté strojom – nevyplýva z nich žiadne tvrdenie o dôkaze.